Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.
Richardson PG, Chanan-Khan AA, Lonial S, Krishnan AY, Carroll MP, Alsina M, Albitar M, Berman D, Messina M, Anderson KC. Richardson PG, et al. Among authors: albitar m. Br J Haematol. 2011 Jun;153(6):729-40. doi: 10.1111/j.1365-2141.2011.08664.x. Epub 2011 Apr 28. Br J Haematol. 2011. PMID: 21534941 Free article. Clinical Trial.
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, Cusack JC Jr, Fenical W, Ghobrial IM, Groll M, Jensen PR, Lam KS, Lloyd GK, McBride W, McConkey DJ, Miller CP, Neuteboom ST, Oki Y, Ovaa H, Pajonk F, Richardson PG, Roccaro AM, Sloss CM, Spear MA, Valashi E, Younes A, Palladino MA. Potts BC, et al. Among authors: albitar mx. Curr Cancer Drug Targets. 2011 Mar;11(3):254-84. doi: 10.2174/156800911794519716. Curr Cancer Drug Targets. 2011. PMID: 21247382 Free PMC article. Review.
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, Wierda W, Ferrajoli A, Kornblau S, Pierce S, Albitar M, Cortes J, Kantarjian H. Giles FJ, et al. Among authors: albitar m. Br J Haematol. 2007 Feb;136(4):624-7. doi: 10.1111/j.1365-2141.2006.06476.x. Br J Haematol. 2007. PMID: 17223919 Free article.
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).
Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG. Alatrash G, et al. Among authors: albitar m. Br J Haematol. 2010 Feb;148(3):386-93. doi: 10.1111/j.1365-2141.2009.07965.x. Epub 2009 Nov 6. Br J Haematol. 2010. PMID: 19895616 Free PMC article. Clinical Trial.
324 results